Risky Mitral Valve Calculator

Clinical calculation support · Verify results before clinical use

Echocardiographic Feature Checklist

Record the presence or absence of each listed finding. This tool does not calculate a validated clinical risk score.

0/9 Findings

Important: The original weighted points and percentage conversion are not supported by a validated scoring model in the supplied code. The calculator therefore reports only the number of selected features and does not convert it into a risk percentage or risk category.

1

Leaflet thickening

Thickening of one or both mitral valve leaflets.

Checklist item
2

Leaflet calcification

Calcification involving the mitral valve leaflets.

Checklist item
3

Restricted leaflet motion

Reduced mobility of one or both leaflets.

Checklist item
4

Annulus dilation >40 mm

Record whether the measured mitral annular diameter exceeds 40 mm; measurement method and phase should be documented.

Checklist item
5

Subvalvular apparatus abnormality

Abnormality involving chordae tendineae or papillary muscles.

Checklist item
6

Mitral valve area <1.5 cm²

Enter yes only when the measured mitral valve area is below 1.5 cm².

Checklist item
7

Mean transmitral gradient >10 mmHg

Interpret with heart rate, rhythm, and flow state.

Checklist item
8

Pulmonary hypertension

Use the echocardiographic/hemodynamic definition documented in the clinical record.

Checklist item
9

Left atrial thrombus

Thrombus identified by appropriate cardiac imaging.

Checklist item
0 of 9 findings
Checklist summary
No features selected
0 of 9 listed findings are marked present.
Clinical interpretation

This is a descriptive checklist only. It is not a validated risk score and must not be used alone to determine procedural eligibility, prognosis, or treatment.

Clinical context

Echocardiography is central to diagnosing mitral valve disease and assessing its anatomy, severity, hemodynamic consequences, prognosis, and suitability for intervention. The findings listed here are heterogeneous descriptors and should not be treated as equally weighted predictors.

How to use this checklist

  • Mark each feature only after reviewing the relevant imaging and clinical measurements.
  • Document the measurement method, rhythm, heart rate, loading conditions, and source imaging where relevant.
  • Assess mitral valve area, mean transmitral gradient, pulmonary pressure, valve morphology, subvalvular anatomy, symptoms, and comorbidities as a complete clinical picture.
  • For suspected left atrial thrombus or before percutaneous mitral commissurotomy, use appropriate imaging and follow current guideline-based pathways.

Interpretation limits

The original code assigned arbitrary weights (1–3 points) and multiplied the sum by 5 to estimate a percentage. No derivation cohort, validation study, calibrated outcome, or evidence supporting these weights and percentages was provided. Those calculations have therefore been removed rather than presented as clinical risk estimates.

Original componentImplementation decision
Weighted pointsRemoved; weights were not validated in the supplied source.
Estimated risk percentageRemoved; score × 5 is not a supported probability model.
Risk category / management adviceNot assigned from checklist count.
Feature selectionRetained as a descriptive yes/no checklist.

References

Vahanian A, Beyersdorf F, Praz F, et al. ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 2022;43(7):561–632. DOI: 10.1093/eurheartj/ehab395. The guideline discusses echocardiographic assessment of mitral stenosis, mitral valve area, mean gradient, pulmonary pressures, valve anatomy, and assessment for left atrial thrombus before percutaneous mitral commissurotomy. Read the guideline (DOI)
2021 ESC/EACTS Guidelines for the management of valvular heart disease — PubMed record. PMID: 34453161. DOI: 10.1093/ejcts/ezab389 (European Journal of Cardio-Thoracic Surgery version). View PubMed record
Clinical disclaimer: This checklist is an educational aid, not a validated prognostic instrument. It does not replace comprehensive echocardiographic assessment, clinical evaluation, guideline-based decision-making, or Heart Team discussion. A mitral valve area below 1.5 cm² is a guideline-relevant threshold for clinically significant rheumatic mitral stenosis; it should not be interpreted in isolation or as a standalone indication for intervention.